Epstein-Barr virus (EBV) and the chronic fatigue syndrome: normal virus load in blood and normal immunologic reactivity in the EBV regression assay.

The etiology of chronic fatigue syndrome (CFS) is unknown. Some patients have high antibody titers to viral capsid antigen (VCA) and early antigen (EA) of Epstein-Barr virus (EBV), suggesting that reactivation of EBV is involved. We investigated virus load (spontaneous transformation) and immunologic regression of EBV-induced transformation in peripheral blood mononuclear cells (PBMCs) from 10 selected patients with CFS who had high antibody titers to VCA and EA. The outcome was compared with that for nine healthy controls and one patient with severe chronic active EBV infection (SCAEBV). There were no significant differences in viral load between patients and healthy controls. Immunologic regression of in vitro-transformed PBMCs was also equally efficient in patients and controls. The SCAEBV-infected patient and two controls, who were all seronegative for EBV, showed impaired regression. In conclusion, we were unable to demonstrate a role for reactivation of EBV in CFS, even in selected patients with high titers of antibody to VCA and EA of EBV.

[1]  J. Levy,et al.  Chronic fatigue syndrome: clinical condition associated with immune activation , 1991, The Lancet.

[2]  M. Sharpe,et al.  A Report–Chronic Fatigue Syndrome: Guidelines for Research , 1991, Journal of the Royal Society of Medicine.

[3]  Y. Sakiyama,et al.  Severe chronic active Epstein-Barr virus infection syndrome , 1991, Clinical Microbiology Reviews.

[4]  C. Sumaya Serologic and virologic epidemiology of Epstein-Barr virus: relevance to chronic fatigue syndrome. , 1991, Reviews of infectious diseases.

[5]  J. F. Jones Serologic and immunologic responses in chronic fatigue syndrome with emphasis on the Epstein-Barr virus. , 1991, Reviews of infectious diseases.

[6]  M. Fletcher,et al.  Immunologic abnormalities in chronic fatigue syndrome , 1990, Journal of clinical microbiology.

[7]  M. Caligiuri,et al.  Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome. , 1987, Journal of immunology.

[8]  J. Sissons,et al.  Epstein Barr virus-specific immune defects in patients with persistent symptoms following infectious mononucleosis. , 1986, The Quarterly journal of medicine.

[9]  W. Henle,et al.  Long-term serological follow-up of patients for Epstein-Barr virus after recovery from infectious mononucleosis. , 1985, The Journal of infectious diseases.

[10]  W. Henle,et al.  Characteristic T cell dysfunction in patients with chronic active Epstein-Barr virus infection (chronic infectious mononucleosis). , 1985, Journal of immunology.

[11]  R. Davey,et al.  Persisting illness and fatigue in adults with evidence of Epstein-Barr virus infection. , 1985, Annals of internal medicine.

[12]  M. Epstein,et al.  T-cell-mediated regression of "spontaneous" and of Epstein-Barr virus-induced B-cell transformation in vitro: studies with cyclosporin A. , 1984, Cellular immunology.

[13]  E. Ben-Chetrit,et al.  PROLONGED ATYPICAL ILLNESS ASSOCIATED WITH SEROLOGICAL EVIDENCE OF PERSISTENT EPSTEIN-BARR VIRUS INFECTION , 1982, The Lancet.

[14]  L. Reed,et al.  A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS , 1938 .